Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CDT Equity Inc. stock logo
CDT
CDT Equity
$1.33
-1.5%
$2.05
$1.29
$274.80
$4.13M1.93136,386 shs144,599 shs
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$1.39
-2.0%
$1.65
$1.20
$3.35
$4.54M0.87104,880 shs15,246 shs
Onconetix, Inc. stock logo
ONCO
Onconetix
$2.93
-2.3%
$3.67
$2.61
$552.50
$4.64M3.37137,925 shs19,886 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.50
+11.1%
$0.76
$0.25
$1.40
$1.30M1.12,972 shs1,113 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CDT Equity Inc. stock logo
CDT
CDT Equity
-5.59%-12.34%-28.19%-59.09%-99.36%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
+0.29%-5.14%-19.31%-12.25%-92.94%
Onconetix, Inc. stock logo
ONCO
Onconetix
+2.04%+6.76%-17.13%-52.24%-99.37%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-12.70%-35.70%-51.33%-91.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CDT Equity Inc. stock logo
CDT
CDT Equity
0.2233 of 5 stars
0.03.00.00.02.20.00.0
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
1.1189 of 5 stars
0.04.00.00.03.80.00.6
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.4334 of 5 stars
0.04.00.00.00.02.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CDT Equity Inc. stock logo
CDT
CDT Equity
0.00
N/AN/AN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.00
N/AN/AN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
0.00
N/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CDT Equity Inc. stock logo
CDT
CDT Equity
N/AN/AN/AN/A$1.15 per shareN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
$4.40M1.03N/AN/A$0.70 per share1.99
Onconetix, Inc. stock logo
ONCO
Onconetix
$2.52M1.80N/AN/A$3.82 per share0.77
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K3.35N/AN/A($2.59) per share-0.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CDT Equity Inc. stock logo
CDT
CDT Equity
-$17.80M-$435.00N/AN/AN/AN/A-350.23%11/12/2025 (Estimated)
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
-$3.08MN/A0.00N/A-85.56%-63.93%-31.42%N/A
Onconetix, Inc. stock logo
ONCO
Onconetix
-$58.69MN/A0.00N/A-3,327.03%-192.74%-89.55%N/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/A-383.58%11/12/2025 (Estimated)

Latest VCNX, CPHI, ONCO, and CDT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
CDT Equity Inc. stock logo
CDT
CDT Equity
N/A-$5.46N/A-$5.46N/AN/A
8/14/2025Q2 2025
Onconetix, Inc. stock logo
ONCO
Onconetix
N/A-$4.05N/A-$4.76N/A$0.11 million
6/12/2025Q1 2025
Onconetix, Inc. stock logo
ONCO
Onconetix
N/A$21.25N/A-$0.53N/A$0.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CDT Equity Inc. stock logo
CDT
CDT Equity
N/AN/AN/AN/AN/A
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/AN/AN/AN/AN/A
Onconetix, Inc. stock logo
ONCO
Onconetix
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CDT Equity Inc. stock logo
CDT
CDT Equity
N/A
1.45
1.45
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
0.22
0.79
0.26
Onconetix, Inc. stock logo
ONCO
Onconetix
N/A
0.07
0.06
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
CDT Equity Inc. stock logo
CDT
CDT Equity
3.29%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
N/A
Onconetix, Inc. stock logo
ONCO
Onconetix
23.89%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%

Insider Ownership

CompanyInsider Ownership
CDT Equity Inc. stock logo
CDT
CDT Equity
7.72%
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
17.32%
Onconetix, Inc. stock logo
ONCO
Onconetix
3.10%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
CDT Equity Inc. stock logo
CDT
CDT Equity
33.06 million2.83 millionNot Optionable
China Pharma Holdings, Inc. stock logo
CPHI
China Pharma
2503.26 million15.92 millionNot Optionable
Onconetix, Inc. stock logo
ONCO
Onconetix
121.55 million1.50 millionN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
402.60 million1.26 millionNo Data

Recent News About These Companies

Vaccinex director resigns, no disagreement cited
Vaccinex to delist common stock from Nasdaq
Pepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of Approval
Vaccinex receives delisting notification from Nasdaq
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
Vaccinex Shares Tumble 63% On Nasdaq Delisting

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT Equity stock logo

CDT Equity NASDAQ:CDT

$1.33 -0.02 (-1.48%)
Closing price 04:00 PM Eastern
Extended Trading
$1.32 -0.02 (-1.13%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

China Pharma stock logo

China Pharma NYSE:CPHI

$1.39 -0.03 (-2.04%)
Closing price 03:55 PM Eastern
Extended Trading
$1.38 -0.01 (-0.43%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Onconetix stock logo

Onconetix NASDAQ:ONCO

$2.93 -0.07 (-2.33%)
Closing price 03:59 PM Eastern
Extended Trading
$2.98 +0.04 (+1.54%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$0.50 +0.05 (+11.09%)
As of 02:45 PM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.